Polymeric Nanoparticles for Drug Delivery in Osteoarthritis

Adriano P Pontes, Tim J M Welting, Jaap Rip, Laura B Creemers*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

Osteoarthritis (OA) is a degenerative musculoskeletal disorder affecting the whole synovial joint and globally impacts more than one in five individuals aged 40 and over, representing a huge socioeconomic burden. Drug penetration into and retention within the joints are major challenges in the development of regenerative therapies for OA. During the recent years, polymeric nanoparticles (PNPs) have emerged as promising drug carrier candidates due to their biodegradable properties, nanoscale structure, functional versatility, and reproducible manufacturing, which makes them particularly attractive for cartilage penetration and joint retention. In this review, we discuss the current development state of natural and synthetic PNPs for drug delivery and OA treatment. Evidence from in vitro and pre-clinical in vivo studies is used to show how disease pathology and key cellular pathways of joint inflammation are modulated by these nanoparticle-based therapies. Furthermore, we compare the biodegradability and surface modification of these nanocarriers in relation to the drug release profile and tissue targeting. Finally, the main challenges for nanoparticle delivery to the cartilage are discussed, as a function of disease state and physicochemical properties of PNPs such as size and surface charge.

Original languageEnglish
Article number2639
Number of pages25
JournalPharmaceutics
Volume14
Issue number12
DOIs
Publication statusPublished - 29 Nov 2022

Cite this